A multicenter long‐term study of imatinib treatment for Japanese patients with unresectable or recurrent gastrointestinal stromal tumors. Issue 8 (28th August 2014)

• Record Type: Journal Article
• Authors: Ogata, Kyoichi; Mochiki, Erito; Ojima, Hitoshi; Haga, Norihiro; Fukuchi, Minoru; Aihara, Ryuusuke; Ando, Hiroyuki; Uchida, Nobuyuki; Toyomasu, Yoshitaka; Suzuki, Masaki; Kimura, Akiharu; Kogure, Norimichi; Yokobori, Takehiko; Ohno, Tetsuro; Kuwano, Hiroyuki
• Is Part Of: Journal of surgical oncology. Volume 110:Issue 8(2014:Dec. 15)
• Page Start: 942
• Page End: 946
• Publication Date: 2014-08-28
• Subjects: Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.23773
• Languages: English
• ISSNs: 0022-4790

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="jso23773-sec-0001" sec-type="section"> <title>Background and Objectives</title> <p>This multicenter study, which was conducted in northern Kanto, Japan, aimed to assess the efficacy of imatinib mesylate against advanced or recurrent gastrointestinal stromal tumors (GIST).</p> </sec> <sec id="jso23773-sec-0002" sec-type="section"> <title>Methods</title> <p>The clinicopathological data of 234 GIST patients who were treated at one of the 11 participating hospitals from 2001–2011 were retrospectively reviewed. Imatinib was administered as a first‐line therapy in cases involving unresectable disease or postoperative recurrence (41 cases). The median follow‐up period was 4.0 years.</p> </sec> <sec id="jso23773-sec-0003" sec-type="section"> <title>Results</title> <p>After a median follow‐up period of 4.0 years, the patients treated with imatinib (n = 41) exhibited 1‐, 3‐, and 5‐year overall survival (OS) rates of 92.3%, 74.9%, and 53.8%, respectively. In univariate and multivariate analyses, imatinib dose reduction and achieving a complete or partial response were found to be associated with increased OS.</p> </sec> <sec id="jso23773-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Long‐term imatinib treatment is recommended for patients with non‐progressive disease. If patients experience significant toxicities, temporary dose reduction might be useful. <italic>J. Surg. Oncol. 2014; 110:942–946</italic>. © 2014 Wiley Periodicals, Inc.</p> </sec> </abstract>